發(fā)布時(shí)間：2018-02-13 03:58

  本文關(guān)鍵詞： 替加環(huán)素 頭孢哌酮舒巴坦 多重耐藥鮑曼不動(dòng)桿菌 肺炎 不良反應(yīng)　出處：《中國(guó)醫(yī)院藥學(xué)雜志》2017年20期 　論文類型：期刊論文

【摘要】：目的:探討頭孢哌酮舒巴坦聯(lián)合替加環(huán)素對(duì)多重耐藥鮑曼不動(dòng)桿菌肺炎患者炎癥反應(yīng)的影響。方法:將70例多重耐藥鮑曼不動(dòng)桿菌肺炎患者分為2組,每組35例。對(duì)照組給予替加環(huán)素治療;研究組在對(duì)照組基礎(chǔ)上給予頭孢哌酮舒巴坦治療;采用急性生理與慢性健康評(píng)分Ⅱ(APACHEⅡ)及臨床肺部感染評(píng)分(CPIS)評(píng)估患者病情發(fā)展情況;對(duì)比2組療效、細(xì)菌清除率及治療前后炎癥反應(yīng)變化。結(jié)果:2組治療后的APACHEⅡ評(píng)分、CPIS評(píng)分較治療前均明顯降低(P0.05);治療后,研究組的APACHEⅡ評(píng)分、CPIS評(píng)分明顯低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05);研究組治療后的總有效率明顯高于對(duì)照組(77.14%vs.37.14%),差異具有顯著性意義(P0.05);研究組患者細(xì)菌清除率達(dá)到65.71%,明顯高于對(duì)照組37.14%,差異有統(tǒng)計(jì)學(xué)意義(P0.05);治療后,2組降鈣素原(PCT)、C反應(yīng)蛋白(CRP)、白細(xì)胞計(jì)數(shù)(WBC)水平均顯著降低(P0.05);研究組治療后PCT、CRP、WBC的水平顯著低于對(duì)照組治療后,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:頭孢哌酮舒巴坦聯(lián)合替加環(huán)素治療多重耐藥鮑曼不動(dòng)桿菌肺炎,能顯著提高細(xì)菌清除率,進(jìn)一步減輕炎癥反應(yīng)。
[Abstract]:Objective: to investigate the effect of cefoperazone sulbactam combined with tegicycline on inflammatory reaction in patients with multidrug resistant Acinetobacter baumannii pneumonia. Methods: 70 patients with multidrug resistant Acinetobacter baumannii pneumonia were divided into two groups. 35 cases in each group were treated with tegicycline in the control group, cefoperazone sulbactam was given in the study group on the basis of the control group, acute physiological and chronic health score 鈪，

本文編號(hào)：1507268